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Background
The EDCTP has currently funded the Central African Net-
work on Tuberculosis, HIV/AIDS and Malaria for the con-
duct of clinical trials because of the paucity of capacity to
conduct clinical trials in this region. However, the com-
plexity of the HIV epidemic lends itself to the develop-
ment of innovative technology to accelerate the
utilization of new tools, such as vaccines, for its control.
This is more so as this region is known to abound in
genetic diversity of the HIV virus.
Methods
Within the programme, relatively strong teams are linked
with weaker units to create interest groups in HIV vaccine
trials and networks. This would require training of indi-
vidual scientists in GCLP, the recruitment and retention of
volunteers, community engagement, data management
and ownership of data, and ethical considerations for the
conduct of trials. It would also require structural and
infrastructural development, procedural arrangemets in
both the strong and weak sites. Training will be conducted
both within the region and outside the region in estab-
lished international clinical trial sites. For ease of reten-
tion of trainees, individuals with advanced qualifications
or those with fixed positions will have an edge in the
selection process so as to ensure sustainability.
Results
It is expected that within three years, individuals would
have been trained in all relevant aspects of clinical trials,
structural and infrastructural arrangements would have
been made in the weak institutions, procedural matters
would have been finalised both within and among the
institutions in the network, the network would be in a
position to conduct clinical trials according to interna-
tional norms.
Conclusion
The diversity in HIV clades in the Central African Region
makes it ideal for the conduct of quality studies on patho-
genesis and vaccine trials. The EDCTP model of selectively
identifying weak instutions for capacity development
bears promise for retaining staff and sustaining gains.
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